Samuraciclib (CT7001) is a potent, selective, and orally active CDK7 inhibitor with an ATP-competitive nature, effectively inhibiting CDK7 with an IC50 of 41 nM. It demonstrates 45-fold, 15-fold (IC50 of 578 nM), 230-fold, and 30-fold selectivity over CDK1, CDK2, CDK5, and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values of 0.2-0.3 µM and possesses anti-tumor effects [1] [2].
Molecular Weight:
394.51
CAS Number:
[1805833-75-3]
Formula:
C22H30N6O
Target:
Others|||CDK|||Apoptosis
T61835
* VAT and and shipping costs not included. Errors and price changes excepted
